Abstract：Diabetic kidney disease is an abnormal pathological change in the structure and function of the kidney caused by diabetic chronic microangiopathy. It is one of the most common complications in the middle and advanced stages of diabetes. It is also the leading cause of death in diabetic patients. Because of the complex pathogenesis of diabetic nephropathy, there is no effective treatment to prevent or slow the occurrence and development of diabetic nephropathy now. With the deep studies of vitamin D and its receptors in the past years, it has been found that vitamin D can regulate calcium and phosphorus metabolism and maintain bone structure. In many clinical and animal experimental studies, it has been observed that there is a certain correlation between vitamin D deficiency and diabetic kidney disease. Vitamin D can postpone the progression of diabetic kidney disease through related mechanisms such as anti-inflammatory, anti-oxidative stress, inhibition of renin-angiotensin-aldosterone system activity, and protection of podocyte. This article reviews the related effects and research progress of vitamin D and its receptors on the pathogenesis of diabetic kidney disease.
付佳 徐琪 韩睿. 维生素D及其受体在糖尿病肾病发病中的研究进展[J]. 中国医药导报, 2020, 17(7): 23-26.
FU Jia XU Qi HAN Rui. Research progress of vitamin D and its receptor in the pathogenesis of diabetic kidney disease. 中国医药导报, 2020, 17(7): 23-26.
[1] Maric C. Sex，diabetes and the kidney [J]. Am J Physiol Renal Physiol，2009，296（4）：680-688.
[2] Ibrahim AH，Omar HH，Imam AM，et al. 25-hydroxyvitamin D Deficiency and Predictive Factors in Patients with Diabetic Nephropathy in Type 2 Diabetes Mellitus [J]. Egypt J Immunol，2018，25（2）：11-20.
[3] Ruggenenti P，Cravedi P，Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy [J]. Nat Rev Nephrol，2010，6（6）：319-330.
[4] Namazi SN，Saberi FS，Falak R，et al. Phosphodiesterase 4 and 7 inhibitors produce protective effects against high glucose-induced neurotoxicity in PC12 cells via modulation of the oxidative stress，apoptosis and inflammation pathways [J]. Metab Brain Dis，2019， 33（4）：1293-1306.
[5] Luis-Rodríguez D，Martínez-Castelao A，Górriz JL，et al. Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy [J]. World J Diabetes，2012，3（1）：7-18.
[6] Ahmad J. Management of diabetic nephropathy： Recent progress and future perspective [J]. Diabetes Metab Syndr，2015，9（4）：343-358.
[7] Duran-Salgado MB，Rubio-Guerra AF. Diabetic nephropathy and Inflammation [J]. World J Diabetes，2014，5（3）：393-398.
[8] Haoran D，Qingquan L，Baoli L. Research Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy [J]. J Diabetes Res，2017，2017：1-10.
[9] Lin YC，Chang YH，Yang SY，et al. Update of pathophysiology and management of diabetic kidney disease [J]. J Formos Med Assoc，2018，117（8）：662-675.
[10] Issa CM. Vitamin D and Type 2 Diabetes Mellitus [J].Adv Exp Med Biol，2017，996：193-205.
[11] Hu X，Liu W，Yan Y，et al. Vitamin D protects against diabetic nephropathy： evidence-based effectiveness and mechanism [J]. Eur J Pharmacol，2019，845：91-98.
[12] Guan X，Yang H，Zhang W，et al. Vitamin D receptor and its protective role in diabetic nephropathy [J]. Chin Med J （Engl），2014，127（2）：365-369.
[13] 王雪，李英.维生素D延缓糖尿病肾病的研究进展[J].临床荟萃，2018，33（3）：267-270.
[14] Deng X，Cheng J，Shen M. Vitamin D improves diabetic nephropathy in rats by inhibiting renin and relieving oxidative stress [J]. J Endocrinol Invest，2016 ，39（6）：657-666.
[15] Li YC，Kong J，Wei M，et al. 1,25-Dihydroxyvitamin D（3） is a negative endocrine regulator of the renin-angiotensin system [J]. J Clin Invest，2002，110（2）：229-238.
[16] Chandel N，Ayasolla K，Wen H，et al. Vitamin D Receptor Deficit Induces Activation of Renin Angiotensin System Via SIRT1 Modulation in Podocytes [J]. Exp Mol Pathol，2017，102（1）：97-105.
[17] Rui X，Dingkun G，Liyang Z，et al. Mechanistic Insight and Management of Diabetic Nephropathy： Recent Progress and Future Perspective [J]. J Diabetes Res，2017， 2017：1-7.
[18] Rai P，Singh T，Lederman R，et al. Hyperglycemia enhances kidney cell injury in HIVAN through down-regulation of vitamin D receptors [J]. Cell Signal，2015，27（3）：460-469.
[19] Thethi TK，Bajwa MA，Ghanim H，et al. Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease [J]. J Diabetes Complications，2015，29（3）：433-437.
[20] Nakai K，Fuj H，Kono K，et al. Vitamin D activates the Nrf2-Keap1 antioxidant pathway and ameliorates nep-hropathy in diabetic rats [J]. Am J Hypertens，2014，27（4）：586-595.
[21] Deb DK，Chen Y，Zhang Z，et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-κB pathway [J]. Am J Physiol Renal Physiol，2009，296（5）：F1212-F1218.
[22] Chokhandre MK，Mahmoud MI，Hakami T，et al. Vitamin D & its analogues in type 2 diabetic nephropathy： a systematic review [J]. J Diabetes Metab Disord，2015，4：58.
[23] Silvia L，Adriana A，Giovanna S，et al. Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease [J]. Int J Endocrinol，2015，2015：1-8.
[24] Gembillo G，Cernaro V，Salvo A，et al. Role of Vitamin D Status in Diabetic Patients with Renal Disease [J]. Medicina （Kaunas），2019，55（6）：273.
[25] Sanchez-Niño MD，Bozic M，Córdoba-Lanús E，et al. Beyond proteinuria： VDR activation reduces renal inflammation in experimental diabetic nephropathy [J]. Am J Physiol Renal Physiol，2012，302（6）：F647-657.
[26] Yu Q，Qiao Y，Liu D，et al. Vitamin D protects podocytes from autoantibodies induced injury in lupus nephritis by reducing aberrant autophagy [J]. Arthritis Res Ther，2019，21（1）：19.
[27] Wang H，Wang J，Qu H，et al. In vitro and in vivo inhibition of mTOR by 1，25-dihydroxy vitamin D3 to improve early diabetic nephropathy via the DDIT4/TSC2/mTOR pathway [J]. Endocrine，2016，54（2）：348-359.
2020, Vol. 17 
京公网安备 11010502046598号